Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Coinbase Global, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.76 (market cap $5.07B), while Coinbase Global, Inc. trades at $148.38 (market cap $39.20B). The key difference: Coinbase Global, Inc. is far larger — about 7.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | COIN | |
|---|---|---|
Market Cap | $5.07B | $39.20B |
Sector | Health | Technology |
52-Week High | $29.41 | $387.27 |
52-Week Low | $20.06 | $141.09 |
Enterprise Value | $4.19B | $36.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
COIN stock trades at $148.68, down 3.2% in the last session amid bearish technical signals and recent earnings misses. The company reported Q2 2026 revenue and EPS below expectations, marking the third consecutive quarterly loss despite achieving record 10.3% global trading volume share. Analyst sentiment remains mixed with 55% buy ratings but a Zacks strong sell designation on August 6, 2026. Technical indicators show bearish momentum with support at $141 and resistance at $152.
The outlook remains challenging with projected 2026 revenue decline to $6.3B and net loss of $988M. While the company maintains strong cash flow from operations ($2.4B in 2025) and is expanding into AI payment solutions, persistent earnings misses and crypto market volatility pose significant risks. The consensus price target of $207.20 suggests 39% upside potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
